Microorganismos probióticos y salud

  1. María Teresa Sánchez
  2. María Adolfina Ruiz
  3. María Encarnación Morales
Aldizkaria:
Ars pharmaceutica

ISSN: 2340-9894,  0004-2927

Argitalpen urtea: 2015

Alea: 56

Zenbakia: 1

Orrialdeak: 45-59

Mota: Artikulua

DOI: 10.4321/S2340-98942015000100007 DIALNET GOOGLE SCHOLAR lock_openSarbide irekia editor

Beste argitalpen batzuk: Ars pharmaceutica

Garapen Iraunkorreko Helburuak

Laburpena

Objetivo: Mostrar los beneficios de los microorganismos probióticos sobre la salud y su aceptación por parte del consumidor, así como hacer una recopilación de todos los productos probióticos disponibles en el mercado farmacéutico. Material y métodos: Se realizó un estudio del mercado farmacéutico en relación a las formas farmacéuticas con microorganismos probióticos existentes y su evolución en los últimos años. La clasificación de todos los productos probióticos se llevó a cabo en función de la forma farmacéutica en la que se presentan;cada producto irá acompañado de la dosis de microorganismos probióticos que contiene, expresada como Unidades Formadoras de Colonias (UFC). Resultados: Es cada vez mayor el número de cepas probióticas aisladas y los beneficios mostrados sobre la salud del hombre. Encontramos gran diversidad de productos probióticos disponibles en oficinas de farmacia como consecuencia de una demanda cada vez mayor por parte del consumidor; no obstante, cabe resaltar el hecho de que muchos de ellos carecen en envase de información necesaria, por ejemplo, la dosis contenida. Conclusiones: El interés por parte de la industria farmacéutica en lazar nuevas formas farmacéuticas contenidas en microorganismos probióticos será cada vez mayor e irá ligado a la necesidad de una reglamentación específica para estos productos. Muchos de ellos no contienen la dosis mínima requerida para obtener un efecto beneficioso en la salud lo que supone una publicidad engañosa para el consumidor, por tanto, deberían ser retirados del mercado, publicitando únicamente aquellos que contengan una dosis terapéutica y cuyos efectos estén avalados por diferentes ensayos clínicos.

Erreferentzia bibliografikoak

  • Champagne, CP, Ross, RP, Saarela, M, Hansen, KF, Charalampopoulos, D. (2011). Recommendations for the viability assessment of probiotics as concentrated cultures and in food matrices. Int J Food Microbiol.. 149. 185-193
  • Dubey, AP, Rajeshwari, K, Chakravarty, A, Famularo, G. (2008). Use of VSL#3 in the treatment of rotavirus diarrhea in children: preliminary results. J Clin Gastroenterol.. 42. 126-129
  • Hempel, S, Newberry, SJ, Maher, AR, Wang, Z, Miles, JN, Shanman, R. (2012). Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA. 307. 1959-69
  • De Vrese, M, Offick, B. (2010). Probiotics and Prebiotics: Effects on Diarrhea. Bioactive Foods in Promoting Health: Probiotics and Prebiotics.
  • Meijer, BJ, Dieleman, LA. (2011). Probiotics in the treatment of human inflammatory bowel diseases. J Clin Gastroenterol.. 45. 139-144
  • Guslandi, M. (2000). Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci.. 45. 1462-1464
  • Montalto, M, Curigliano, V, Santoro, L. (2006). Management and treatment of lactose malabsorption. World J Gastroenterol.. 12. 187-191
  • Gotteland, M, Brunser, O, Cruchet, S. (2006). Systematic review: are probiotics useful in controlling gastric colonization by Helicobacter pylori?. Aliment Pharmacol Ther.. 23. 1077-1086
  • Alexandre, Y, Le Blay, G, Boisramé-Gastrin, S, Le Gall, F, Héry-Arnaud, G, Gouriou, S, Vallet, S, Le Berre, R. (2014). Probiotics: A new way to fight bacterial pulmonary infections?. Med Mal Infect.. 44. 9-17
  • Larsen, LA, Raben, A, Haulrik, N, Hansen, AS, Manders, M, Astrop, A. (2000). Effect of 8 week intake of probiotic milk products on risk factors for cardiovascular diseases. Eur J Clin Nutr.. 54. 288-297
  • Xiao, JZ, Kondo, S, Takahashi, N. (2003). Effects of milk products fermented by Bifidobacteriumlongum on blood lipids in ratsand healthy adult male volunteers. J Dairy Sci.. 86. 2452-2461
  • Tulika, A, Satvinder, S, Kumar Sharma, R. (2013). Probiotics: Interaction with gut microbiome and antiobesity potential. Nutrition. 29. 591-596
  • Qin, J, Li, Y, Cai, Z, Li, S. (2012). A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 490. 55-60
  • Waligora-Dupriet, AJ, Butel, MJ. (2012). Microbiota and allergy: from dysbiosis to probiotics. Allergic diseases-highlights in the clinic, mechanisms and treatment. 413-434
  • Ozdemir, O. (2010). Various effects of different probiotic strains in allergic disorders: an update from laboratory and clinical data. Clin Exp Immunol.. 160. 295-304
  • Bunselmeyer, B, Buddendick, K. (2010). Probiotics and Prebiotics-Prevention and Therapy in Atopic Eczema. Bioactive Foods in Promoting Health: Probiotics and Prebiotics.
  • Serban, DE. (2013). Gastrointestinal cancers: Influence of gut microbiota, probiotics and prebiotics. Cancer letter.. 345. 258-270
  • Iannitti, T, Palmieri, B. (2010). Therapeutical use of probiotic formulations in clinical practice. Clinical Nutrition. 29. 701-725
  • Theodorakopoulou, M, Perros, E, Giamarellos-Bourboulis, EJ, Dimopoulos, G. (2013). Controversies in the management of the critically ill: the role of probiotics. Int J Antimicrob Agents. 42. S41-S44
  • Gupta, V, Garg, R. (2009). Probiotics. Indian J Med Microbiol.. 136. 2015-2031
  • Huang, Y, Adams, MC. (2004). In vitro assessment of the upper gastrointestinal tolerance of potential probiotic dairy propionibacteria. Int J Food Microbiol.. 91. 253-260
  • Chaikham, P, Apichartsrangkoon, A, Jirarattanarangsri, W, Van de Wiele, T. (2012). Influence of encapsulated probiotics combined with pressurized longan juice on colon microflora and their metabolic activities on the exposure to simulated dynamic gastrointestinal tract. Food Res Int.. 49. 133-142
  • Foligné, B, Daniel, C, Pot, B. (2013). Probiotics from research to market: the possibilities risk and challenges. Curr Opin Microbiol.. 16. 284-292
  • Brandy, LJ, Gallaher, DD, Busta, FF. (2000). The role of probiotic cultures in the prevention of colon cancer. J Nutr.. 130. 410S-414S
  • Chen, CC, Louie, S, Shi, HN, Walker, WA. (2005). Preinoculation with the probiotic Lactobacillus acidophilus early in life effectively inhibits murine Citrobacterrodentium colitis. Pediatr Res.. 58. 1185-1191
  • De Vrese, M, Offick, B. (2005). Bioactive Foods in Promoting Health. Institute of Physiology and Biochemistry of Nutrition, Federal Dairy Research Center. Kiel. 205-227
  • Elmer, GW, McFarland, LV. (2001). Biotherapeutic agents in the treatment of infectious diarrhea. Gastroenterol Clin.. 30. 837-854
  • Furrie, E. (2005). Probiotics and allergy. Proc Nutr Soc.. 64. 465-469
  • Galvez, J, Comalada, M, Xaus, J. (2010). Prebiotics and Probiotics in Experimental Models of Rodent Colitis: Lessons in Treatment or Prevention of Inflammatory Bowel Diseases. Bioactive Foods in Promoting Health: Probiotics and Prebiotics.
  • Ghadimi, D, Fölster-Holst, R, de Vrese, M, Winkler, P, Heller, KJ, Scherenmeir, J. (2008). Effect of probiotic bacteria and their genomic DNA on Th1/ th2- cytokine production by peripheral blood mononuclear cells of healthy and allergic subjects. Inmunobiology. 213. 677-692
  • Guarino, A, Canani, NB, Spagnuolo, MI. (1997). Oral bacterial therapy reduces the duration of symptons and of viral excretion in children with mild diarrea. J Pediatr Gastroenterol Nutr.. 25. 516-519
  • Homayoni, A, Vaghef, E, Alipoor, B, Vaghef, L, Javadi, M. (2012). Do probiotics act more efficiently in foods than in supplements?. Nutrition. 28. 733-736
  • Kalliomaki, MA, Isoulari, E. (2004). Probiotics and down regulation of the allergic response. Inmunol Allergy Clin North Am.. 24. 739-752
  • Kieran, M, Hollie, M, Chris, W, Glann, R. (2003). Using probiotics and prebiotics toimprove gut health. DDT. 8. 692-700
  • Lara-Villoslada, F, Olivares, M, Xaus, J. (2010). Safety of probiotic bacteria. Bioactive Foods in Promoting Health: Probiotics and Prebiotics. 4. 47-58
  • Lievin, L, Peiffer, V, Hudault, I. (2000). Bifidobacterium strains from resident infant human gastrointestinal microflora exert antimicrobial activity. Gut. 47. 646-652
  • Lin, MY, Yen, CL, Chen, SH. (1998). Management of lactose maldigestion by consuming milk containing Lactobacilli. Dig Dis.. 43. 133-137
  • López, C, De la Cruz, J, Urbanos, C. (2006). Uso potencial de los probióticos. FMC. 13. 622-627
  • Madsen, K, Cornish, A, Soper, P. (2001). Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology. 121. 580-591
  • Marteau, P, Shanahan, F. (2003). Basic aspects and pharmacology of probiotics: an overview of pharmacokinetics, mechanisms of action and side-effects. Best Pract Res Clin Gastroenterol.. 17. 725-740
  • McFarland, LV. (1998). Epidemiology, risk factors and treatments for antibiotic associated diarrhea. Dig Dis.. 16. 292-307
  • Morrison, DJ, Mackay, WG, Edwards, CA. (2006). Butyrate production from oligofructose fermentation by the human faecal flora: What is the contribution of extracellular acetate and lactate?. Br J Nutr.. 96. 570-577
  • Nguyen, TD, Kang, JH, Lee, MS. (2007). Chacarterization of Lactobacillus plantarumPH04, a potential probiotic bacterium with cholesterol-lowering effects. Int J Food Microbiol.. 113. 358-361
  • Ouwehand, AC, Salminen, S, Isolauri, E. (2002). Probiotics: an overview of beneficial effects. Antonie Van Leeuwenhoek. 82. 279-289
  • Patel, A, Shah, N, Prajapati, JB. (2013). Clinical appliance of probiotics in the treatment of Helicobacter pylori infection: a brief review. MikrobiolZh.. XX. 1-9
  • Podolsky, DK. (2002). Inflammatory Bowel Disease. N Engl J Med.. 347. 417-421
  • Preidis, GA, Versalovic, J. (2009). Targeting the human Microbiome with antibiotics, probiotics and prebiotics: gastroenterology enters the metagenomics era. Gastroenterology. 136. 2015-2031
  • Ramos, A, Monteoliva, M, Nader, FE. Probióticos y salud.
  • Sanders, ME, Heimbach, JT, Pot, B. (2011). Health claims substantiation for probiotic and prebiotic products. Gut microbes. 2. 127-133
  • Schultz, M, Linde, HJ, Lehn, N. (2003). Immunomodulatory consequences of oral administration of Lactobacillus rhamnosus strain GG in healthy volunteers. J Dairy Res.. 70. 165-173
  • Talaie, F, Atyabi, F, Azjdarzadeh, M, Dinarvand, R, Saadatzadeh, A. (2013). Overcoming therapeutic obstacles in inflammatory bowel diseases: A comprehensive review on novel drug delivery strategies. Eur J Pharm Sci.. 49. 712-722
  • Taranto, MP, Medici, M, Perdigon, G, Ruiz Holgado, AP, Valdez, GF. (2000). Evidence for hypocholesterolemic effect of Lactobacillus Reuteri in hypercholesterolemic mice. J Dairy Sci.. 81. 2336-2340
  • Zhu, Y, Luo, M, Jobin, C, Young, H. (2011). Gut microbiota and probiotics in colon tumorigenesis. Cancer Letters. 309. 119-127
  • Zyrek, A A, Cichon, C, Helms, S. (2007). Molecular mechanisms underlying the probiotic effects of Escherichia coli Nissle 1917 involve ZO-2 and PKC zeta redistribution resulting in tight junction and epithelial barrier repair. Cell Microbiol.. 9. 804-816
Datuen iturria: Dialnet